Cargando…
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
Although PD-1-blocking immunotherapies demonstrate significant therapeutic promise, a subset of the patients could develop hyperprogressive disease (HPD) with accelerated tumor growth after anti-PD1 immunotherapy. To elucidate the underlying mechanisms, we compared the mutational and transcriptional...
Autores principales: | Xiong, Donghai, Wang, Yian, Singavi, Arun K., Mackinnon, Alexander C., George, Ben, You, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234258/ https://www.ncbi.nlm.nih.gov/pubmed/30439581 http://dx.doi.org/10.1016/j.isci.2018.10.021 |
Ejemplares similares
-
Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019) -
Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019) -
Establishment of tumor inflammasome clusters with distinct immunogenomic landscape aids immunotherapy
por: Liang, Qingyu, et al.
Publicado: (2021) -
Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023) -
Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)